Protalix BioTherapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Protalix BioTherapeutics şirketinin toplam hissedar öz sermayesi $28.6M ve toplam borcu $20.4M olup, bu da borç-öz sermaye oranını 71.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $91.5M ve $63.0M dir.

Anahtar bilgiler

71.4%

Borç/özkaynak oranı

US$20.42m

Borç

Faiz karşılama oranı	n/a
Nakit	US$45.03m
Eşitlik	US$28.58m
Toplam yükümlülükler	US$62.96m
Toplam varlıklar	US$91.54m

Son finansal sağlık güncellemeleri

Recent updates

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Feb 22

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Jan 14

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Dec 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PLX 'nin kısa vadeli varlıkları ( $77.4M ) kısa vadeli yükümlülüklerini ( $58.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: PLX şirketinin kısa vadeli varlıkları ( $77.4M ) uzun vadeli yükümlülüklerini ( $5.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PLX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: PLX şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PLX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: PLX, serbest nakit akışı her yıl % 0.6 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Protalix BioTherapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

Recent updates

Protalix BioTherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Protalix BioTherapeutics, Inc.(NYSEAM:PLX) dropped from Russell Small Cap Comp Value Index

Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Protalix BioTherapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus revenue estimates increase by 20%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$9.00

President recently bought US$102k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Forecast breakeven pushed back to 2022

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: US$4.91

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: US$4.17

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

New 90-day high: US$3.96

Third quarter earnings released

Third-quarter earnings released: Earnings miss expectations

New 90-day low: US$3.35

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

New 90-day low - US$3.37

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

Price target lowered to US$9.75

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin